Get the Stockscreener App
7.43
0.80%
-0.06
Pre-market:
7.42
-0.010
-0.13%
Mink Therapeutics Inc stock is traded at $7.43, with a volume of 1,007.
It is down -0.80% in the last 24 hours and down -1.46% over the past month.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
See More
Previous Close:
$7.49
Open:
$7.4404
24h Volume:
1,007
Relative Volume:
0.19
Market Cap:
$30.20M
Revenue:
-
Net Income/Loss:
$-24.77M
P/E Ratio:
-10.18
EPS:
-0.73
Net Cash Flow:
$-17.36M
1W Performance:
-2.11%
1M Performance:
-1.46%
6M Performance:
+60.41%
1Y Performance:
-15.29%
1-Day Range:
$7.43
$7.4404
1-Week Range:
$7.20
$7.5729
52-Week Range:
$4.5601
$13.79
Mink Therapeutics Inc Stock (INKT) Company Profile
Name
Mink Therapeutics Inc
Sector
Industry
Phone
212-994-8250
Address
149 FIFTH AVENUE, NEW YORK
Compare INKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
7.43 | 30.20M | 0 | -24.77M | -17.36M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Mink Therapeutics Inc Stock (INKT) Latest News
Where are the Opportunities in (INKT) - news.stocktradersdaily.com
Kalkine: MiNK Therapeutics Sees Gains Amid Positive Earnings Per Share Momentum - Kalkine Media
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting - Eagle-Tribune
MiNK Therapeutics Annual Meeting: How Shareholders Can Join Virtually on June 18 - Stock Titan
MiNK Therapeutics (NASDAQ:INKT) Stock Price Up 0.1% – Here’s Why - Defense World
MiNK Therapeutics receives NIH grant for GvHD therapy - Investing.com India
MiNK Therapeutics, Inc. Awards Prestigious Niaid Grant to Advance Allo-Inkt Cell Therapy for Prevention of Gvhd in Stem Cell Transplant Patients - MarketScreener
INKT Secures Grant for GvHD Cell Therapy Development | INKT Stoc - GuruFocus
MiNK Therapeutics Receives NIAID Grant to Advance Allo-iNKT Cell Therapy for Graft-Versus-Host Disease Treatment - Nasdaq
MiNK Therapeutics Awarded Prestigious NIAID Grant to - GlobeNewswire
NIH Backs Revolutionary Cell Therapy: MiNK's Solution Could Prevent Deadly Transplant Complications - Stock Titan
(INKT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Amer Sports: The New ONON and DECK of Consumer Discretionary? - The Globe and Mail
MiNK Therapeutics outlines near-term partnering proposals and reduced cash burn as company advances iNKT programs - MSN
HC Wainwright Cuts Earnings Estimates for MiNK Therapeutics - Defense World
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2025 Earnings Call Transcript - Insider Monkey
MiNK Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Mink Therapeutics’ Earnings Call Highlights Progress and Optimism - TipRanks
Transcript : MiNK Therapeutics, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
MiNK Therapeutics (INKT) Advances in Immune Response Innovation - GuruFocus
MiNK Therapeutics (INKT) Advances in Immune Response Innovation | INKT Stock News - GuruFocus
MiNK Therapeutics Reports Clinical Advancements and Financial Update for Q1 2025, with Focus on iNKT Cell Therapies - Nasdaq
Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress - GlobeNewswire
MiNK Therapeutics (INKT) Projected to Post Earnings on Tuesday - Defense World
Refractory Multiple Myeloma Pipeline Appears Robust With 75+ - openPR.com
How to Take Advantage of moves in (INKT) - news.stocktradersdaily.com
MiNK Therapeutics to Announce Q1 2025 Financial Results and Host Conference Call on May 15th - Nasdaq
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report - GlobeNewswire
Geode Capital Management LLC Lowers Stock Position in MiNK Therapeutics, Inc. (NASDAQ:INKT) - Defense World
Learn to Evaluate (INKT) using the Charts - news.stocktradersdaily.com
Comparing Atyr PHARMA (NASDAQ:ATYR) and MiNK Therapeutics (NASDAQ:INKT) - Defense World
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia - Business Wire
LIfT BioSciences appoints new CSO - Bdaily
LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer - EIN News
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch - Business Wire
(INKT) Trading Report - news.stocktradersdaily.com
Reviewing MiNK Therapeutics (NASDAQ:INKT) & Creative Medical Technology (NASDAQ:CELZ) - The AM Reporter
HC Wainwright Issues Negative Forecast for INKT Earnings - Defense World
What is William Blair’s Forecast for INKT Q1 Earnings? - Defense World
What is William Blair’s Estimate for INKT Q1 Earnings? - Defense World
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2024 Earnings Call Transcript - Insider Monkey
MiNK Therapeutics (NASDAQ:INKT) Given Buy Rating at HC Wainwright - Defense World
MiNK Therapeutics Inc (INKT) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
MiNK Therapeutics Reports 2024 Progress and Financials - TipRanks
MiNK Therapeutics’ Earnings Call Highlights Strategic Gains - TipRanks
MiNK Therapeutics, Inc. SEC 10-K Report - TradingView
Earnings call transcript: Mink Therapeutics Q4 2024 reports reduced net loss - Investing.com
Mink Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress - GlobeNewswire
MiNK Therapeutics Reports 2024 Financial Results and Highlights Clinical Advancements in iNKT Cell Therapies - Nasdaq
Mink Therapeutics Inc Stock (INKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.13%
1.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):